Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
3(23%)
Results Posted
38%(3 trials)

Phase Distribution

Ph phase_4
4
31%
Ph phase_3
7
54%
Ph phase_1
1
8%

Phase Distribution

1

Early Stage

0

Mid Stage

11

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
1(8.3%)
Phase 3Large-scale testing
7(58.3%)
Phase 4Post-market surveillance
4(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

8 of 8 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

13

all time

Status Distribution
Active(4)
Completed(8)
Other(1)

Detailed Status

Completed8
Recruiting3
unknown1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
3
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (8.3%)
Phase 37 (58.3%)
Phase 44 (33.3%)

Trials by Status

unknown18%
completed862%
not_yet_recruiting18%
recruiting323%

Recent Activity

3 active trials
Showing 5 of 13
completedphase_4

Live Vaccines and Innate Immune Training in COPD.

NCT06257212
recruitingphase_3

A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age

NCT06806137
recruitingphase_3

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

NCT06855160
not_yet_recruitingphase_4

Study of Concomitant Administration of the sIPV and DTaP or MMR

NCT06920069
recruitingphase_3

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

NCT06740630
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT06257212Phase 4

Live Vaccines and Innate Immune Training in COPD.

Completed
NCT06806137Phase 3

A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age

Recruiting
NCT06855160Phase 3

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

Recruiting
NCT06920069Phase 4

Study of Concomitant Administration of the sIPV and DTaP or MMR

Not Yet Recruiting
NCT06740630Phase 3

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

Recruiting
NCT03547271Phase 3

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

Completed
NCT04475081Phase 3

Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis

Completed
NCT00962819

Measles, Mumps, and Rubella (MMR) Immunity in College Students

Completed
NCT01553279Phase 3

Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)

Completed
NCT03853785Phase 3

Efficacy of Intralesional MMR Vaccine,Intralesional Candidal Antigen&Topical Podophyllin in Treatment of Genital Warts

Unknown
NCT02253407Phase 4

Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old Children

Completed
NCT02589678Phase 1

Zambia SiVET MMR Tdap-IPV

Completed
NCT01777529Phase 4

Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations

Completed

All 13 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
13